Biohit Oyj

HLSE:BIOBV Stock Report

Market Cap: €35.7m

Biohit Oyj Future Growth

Future criteria checks 2/6

Biohit Oyj is forecast to grow earnings and revenue by 12.2% and 14.3% per annum respectively while EPS is expected to grow by 12.4% per annum.

Key information

12.2%

Earnings growth rate

12.4%

EPS growth rate

Medical Equipment earnings growth27.2%
Revenue growth rate14.3%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Dec 2024

Recent future growth updates

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17
Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22
Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17
Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Aug 04
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Feb 09
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Aug 11
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Apr 13
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Dec 28
We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

HLSE:BIOBV - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026203231
12/31/2025182231
12/31/2024142331
6/30/2024142-10N/A
3/31/202414200N/A
12/31/202313211N/A
9/30/202312101N/A
6/30/202311100N/A
3/31/202311111N/A
12/31/202211122N/A
9/30/202211111N/A
6/30/202211111N/A
3/31/202210000N/A
12/31/20219-100N/A
9/30/20219-200N/A
6/30/20218-200N/A
3/31/20218-300N/A
12/31/20207-300N/A
9/30/20208-300N/A
6/30/20208-300N/A
3/31/20209-200N/A
12/31/201910-100N/A
9/30/201910-200N/A
6/30/201910-200N/A
3/31/201910-200N/A
12/31/201810-200N/A
9/30/201810-200N/A
6/30/201810-200N/A
3/31/201892N/A-1N/A
12/31/201796N/A-1N/A
9/30/201796N/A-1N/A
6/30/201786N/A-2N/A
3/31/201781N/A-2N/A
12/31/20168-3N/A-2N/A
9/30/20167-4N/A-3N/A
6/30/20166-4N/A-3N/A
3/31/20167-3N/A-3N/A
12/31/20156-3N/A-3N/A
9/30/20156-3N/A-2N/A
6/30/20156-4N/A-3N/A
3/31/20155-4N/A-4N/A
12/31/20144-4N/A-3N/A
9/30/20144-5N/A-4N/A
6/30/20144-5N/A-4N/A
3/31/20144-6N/A-4N/A
12/31/20133-6N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOBV's forecast earnings growth (12.2% per year) is above the savings rate (1.3%).

Earnings vs Market: BIOBV's earnings (12.2% per year) are forecast to grow slower than the Finnish market (14.2% per year).

High Growth Earnings: BIOBV's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIOBV's revenue (14.3% per year) is forecast to grow faster than the Finnish market (2.6% per year).

High Growth Revenue: BIOBV's revenue (14.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIOBV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 01:17
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biohit Oyj is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antti SiltanenInderes Oy